CN101804102A - Traditional Chinese medicine compound for nonalcoholic steatohepatitis - Google Patents
Traditional Chinese medicine compound for nonalcoholic steatohepatitis Download PDFInfo
- Publication number
- CN101804102A CN101804102A CN 201010150807 CN201010150807A CN101804102A CN 101804102 A CN101804102 A CN 101804102A CN 201010150807 CN201010150807 CN 201010150807 CN 201010150807 A CN201010150807 A CN 201010150807A CN 101804102 A CN101804102 A CN 101804102A
- Authority
- CN
- China
- Prior art keywords
- group
- chinese medicine
- condensed
- parts
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine compound for nonalcoholic steatohepatitis, belonging to the technical field of medicines. The traditional Chinese medicine preparation is prepared from the root of red-rooted salvia, polygonum cuspidatum, lucid ganoderma and stringy stonecrop herb, and can be used for treating patients with nonalcoholic steatohepatitis clinically.
Description
Technical field:
The present invention relates to a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition and preparation method that is used for the treatment of non-alcoholic stellato-hepatitis.
Background technology:
Along with The development in society and economy and people's dietary structure, the change of life style, with obesity, the sickness rate of hyperlipidemia and the closely-related non-alcohol fatty liver of diabetes obviously rises, become at present one of clinical common hepatopathy, studies show that, oxidative stress and lipid peroxidation may play an important role in the morbidity of non-alcoholic stellato-hepatitis and disease progression, and the clinical treatment of non-alcoholic stellato-hepatitis does not still have specific medicament so far, we find under study for action, after using the preparation for treating of this pharmaceutical composition, each treatment group presents the serum liver function, SOD, length of schooling in serum and the liver homogenate takes a turn for the better to some extent, liver fat becomes all, inflammation performance and fibrosis Chengdu all alleviate to some extent, illustrate this drug combination preparation can improve non-alcoholic stellato-hepatitis blood fat disorder, alleviate the deposition of fat at liver, promote liver function and histological recovery, and can improve the ability that body is removed oxygen-derived free radicals, at antioxidation, blood lipid regulation, antiinflammatory, aspects such as anti-hepatic fibrosis have unique curative effect.
Summary of the invention
The objective of the invention is to for clinical provide a kind of effective treatment non-alcoholic stellato-hepatitis Chinese medicine composition and preparation method thereof.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight): Radix Salviae Miltiorrhizae 5-15 part, Rhizoma Polygoni Cuspidati 10-30 part, Ganoderma 4-12 part, Herba Sedi 17-51 part.Optimum ratio is: 10 parts of Radix Salviae Miltiorrhizaes, 20 parts of Rhizoma Polygoni Cuspidati, 8 parts of Ganodermas, 34 parts of Herba Sedis.
Manufacturing method for above mentioned medicine is: Herba Sedi partly is ground into fine powder, and remaining Herba Sedi decocts with water secondary, collecting decoction, the thick paste that filters, is condensed into; Other gets Ganoderma, adds alcohol dipping three times, respectively inclines and gets supernatant, and last press residue is collected press juice, merges with three supernatant, filters, and reclaims ethanol and is condensed into thick paste, and is standby; Radix Salviae Miltiorrhizae and Rhizoma Polygoni Cuspidati are made slowly percolation of solvent with ethanol, and the soluble component of waiting is filtered out fully, and percolate reclaims ethanol and is condensed into thick paste; The medicinal residues of Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati and Ganoderma decoct with water secondary, filter the thick paste that filtrate is condensed into, get above-mentioned four kinds of thick pastes, add remaining Herba Sedi fine powder mixing, drying, pulverize, add suitable adjuvant, make capsule, tablet, drop, granule according to conventional operation.
Can effectively treat the patient of non-alcoholic stellato-hepatitis on the clinical drug of the present invention, and have no side effect.
Experimental example one pharmacodynamic experiment
Drug combination preparation main pharmacodynamics result of study of the present invention has confirmed that this pharmaceutical composition has the effect of stronger treatment non-alcoholic stellato-hepatitis disease.
1 data and method
1.1 laboratory animal: male SD rat, the cleaning level provides body weight 137g-197g, every cage 3-5 sub-cage rearing by Guizhou letter nation pharmacy drug research center.
1.2 feedstuff: standard feed is provided by Guizhou letter nation pharmacy drug research center.High lipid food is by Beijing section Australia fresh batching of feed corporation,Ltd of pulling together, credit number: SCXK (capital) 2005-2007, and filling a prescription is: (77.5% standard feed, 15% Adeps Sus domestica, 5% yolk powder, 2% cholesterol, 0.5% sodium cholate).Feedstuff prepares the back and packs with plastic bag sealing, preserves in 4 ℃ of refrigerators.
1.3 medicine: Chinese medicinal composition preparation provides (capsule) by Guizhou letter nation pharmacy drug research center, face with preceding and content is ground to form powdery with grinding, make its medicated powder be dissolved in the suspension of making required concentration in the distilled water, 4 ℃ of fresh-keeping and cold storages, each with before shaking up.
1.4 instrument and reagent Hitachi 7600 and Hitachi's 7170 automatic clinical chemistry analyzers, the SHH-W21-420 constant water bath box.
1.5 serum propylene glycol (MDA) reagent builds up bio-engineering research institute available from Nanjing, adopts sulfuration for barbiturates (TBA) colorimetric analysis, the strict test kit description of pressing detects.Serum superoxide dismutases (SOD) reagent adopts Britain Lang Dao (Randox) reagent, and company provides by Beijing the last nine, detects in strict accordance with the test kit description.
2 test methods
2.1NASH model set up 39 of SD rats, normally feed 1W after, be divided into 2 groups at random according to the body weight level: normal control group (9) and experimental group (30).The normal control group is fed with standard feed, and experimental group is fed with high lipid food.Two groups of equal food and drinking-water of freely obtaining of rat, receptacle with the 80W fluorescent lamp lighting, are carried out 12h light/dark circulation for the cleaning level, and room temperature is set to 22 ℃-28 ℃.11W does not randomly draw 5 rats from the normal control group, and 5% sodium pentobarbital solution carries out intraperitoneal anesthesia, puts to death rat, leaves and takes ventral aorta blood 5ml, and leaves and takes hepatic tissue and do the pathology section, inflammation modeling success; Simultaneously the residue rat is left and taken socket of the eye venous blood 1ml, separation of serum is in order to surveying each biochemical indicator.
2.2 experiment grouping experiment 13W rises, remaining rats in normal control group (X group) is 5, and remaining 25 experimental group rats are weighed, and is divided into 5 groups more at random by the body weight level: the Z group is high fat group, 5; The Y group is Diet Therapy group, 5; The A group is high doses treatment group, 6; The B group is pharmaceutical preparation low dose therapy group, 5.The diet aspect continues to raise with the high lipid food except that the Z group, and all the other each groups are all fed with standard feed.Experimental rat freely drink water and the condition of taking food under, morning every day each group rat is irritated the stomach treatment once, wherein X group, Y group, Z organize the normal saline of capacity such as gavaging every day, A group,, B group, C group then give pharmaceutical preparation suspension oral gavage once, dosage is respectively 700mg/kg/d, 175mg/kg/d, and drug dose calculates by " pharmacological experimental methodology ", and each medication volume is pressed 0.5ml/100g and calculated, the weighing rat is once adjusted dosage in view of the above weekly.Experimental period is 4W altogether.
2.3 collection of specimens and handling after last medication after all water 12h is can't help in the rat fasting, is given 5% sodium pentobarbital solution by 0.1ml/100g body weight/only carry out intraperitoneal anesthesia.To anaesthetize back rat dorsal position and be fixed on the operating-table, and open the abdominal cavity, blood 5ml is got in the ventral aorta puncture, and separation of serum is in order to each biochemical indicator.Put to death rat, complete immediately excision rat liver and intraabdominal adipose tissue (fat that comprises epididymis, kidney week and omentum majus), it is placed 4 ℃ of brine ice rinsings repeatedly respectively, observe liver outward appearance and weighing liver weight in wet base and intraabdominal adipose tissue weight behind the filter paper suck dry moisture.Take by weighing 0.5g hepatic tissue and 0.9 brine ice by 1 in the right lobe of liver same area; 9 ratio homogenate are 10% liver homogenate, centrifugal 15 minutes of 3000rpm.Extract supernatant each biochemical indicator to be measured.Get 0.5cm * 1cm * 0.5cm hepatic tissue at leftlobe of liver and place 10% formalin solution fixing, the paraffin embedding of selecting a time is also made pathological section.
2.4 the whole rats of MAIN OUTCOME MEASURES and detection method (1) duration of test are also write down once in set time weighing weekly, observe appetite, behavior, feces, hair and animal dead situation; (2) conventional separation of serum, test serum ALT, AST, TC, TG, LDLC, GLU, SOD, MDA adopt automatic spectrophotometric method for determination by I research center special messenger; Wherein ALT, AST, TC, TG, LDLC, GLU measure on Hitachi's 7600 full-automatic analysers, and SOD, MDA measure more than Hitachi's 7170 full-automatic biochemicals are analyzed; (3) weighing liver weight in wet base and intraabdominal adipose tissue weight as interior fat content, can be calculated liver index (liver weight in wet base/body weight * 100%) and body fat than (interior fat content/body weight * 100%) with weight in the intraabdominal adipose tissue in above-mentioned three kinds of sources; (4) liver homogenate supernatant TC to be measured, TG, LDLC, MDA, method is identical with the assay method of corresponding index in the serum; (5) each part rat liver specimen is carried out conventional H E dyeing, Masson dyeing and reticular fiber staining respectively, carries out classification and scoring, and wherein F (steatosis Chengdu) is divided into the 0-3 level, and G (inflammation degree) is divided into the 0-3 level, and S (fibrosis) is divided into the 0-4 level.
2.5 statistical method is used SPSS12.0 statistical analysis software deal with data, calculating chart date processing variance analysis between many groups, and date processing is checked with t between two groups, the enumeration data rank test of grade classified data.
3 results
3.1 respectively organize in the rat ordinary circumstance experimentation, it is good that each organizes rat growthing development, do not have rats death when experiment finishes.The rats in normal control group action is active, and is clean and tidy by hair, fine and closely woven submissive; Experimental group rat appetite is good, and disposition is relatively docile, and is fluffy and disorderly and matt by hair, the movable minimizing and blunt.
3.2 the two groups of every results' of rat in 11W end comparison with inflammation modeling success 1. during baseline and 11W end rats in normal control group (n=4) compare difference with experimental group rat (n=5) body weight and do not have significance; 11W end experimental group rats'liver weight in wet base, the normal matched group of liver index obviously increase, and difference has significance (P＜0.05); And experimental group rat interior fat content, body fat comparison normal control group increases, but difference does not have significance.2. serum AST, the TC of experimental group rat, TG, LDLC, GLU, the normal matched group of MDA level increase, and the normal matched group of the SOD in serum level of experimental group rat reduces, and the difference between two groups has significance (P＜0.05).3. the liver homogenate TC of experimental group rat, TG, the normal matched group of MDA level increase, and the difference between two groups has significance (P＜0.05).4. under optical microscope, normal control group liver cell element marshalling, nuclear is big placed in the middle, fat-free and inflammatory cell infiltration; The diffusivity steatosis all appears in experimental group, and with the most obvious around the central vein, nuclear occupies the limit, has significant quantities of fat to drip cavity in the endochylema, and inflammatory cell infiltration is arranged in the lobule, and there is the fibrosis structure in hole week.The change of experimental group hepatic tissue fat, inflammation and the normal matched group of fibrosis increase the weight of, and difference has significance (P＜0.05).
3.3 body weight, liver index, interior fat content and body fat that rat is respectively organized at the 16W end do not have significance than each group rat inchoate aspect heavy phase than difference, respectively organize body weight when experiment finishes and compare difference and do not have significance; Z group liver weight in wet base, liver index significantly increase than other groups, and comparing difference with the C group has significance (P＜0.05); Z group and Y group interior fat content increase than B group, C group, but difference does not have significance; Relatively Y and the reduction of Z group of B group, C group body fat, difference has significance (P＜0.05) (seeing Table).
Table one is respectively organized body weight, liver index, interior fat content and the body fat ratio of rat the 16th weekend
Annotate: X group-normal control group, Y group Diet Therapy group; Z organizes high fat group, A group-high-dose therapy group, B group-middle dosage treatment group, C group-low dose therapy group; Compare P＜0.05. with Y, Z group
3.4 the comparison (seeing Table two) of each biochemical indicator of rat blood serum is respectively organized at the 16W end
Table two is respectively organized each biochemical indicator of rat blood serum the 16th weekend
Annotate: X group-normal control group, Y group Diet Therapy group; Z organizes high fat group, A group-high-dose therapy group, B group-middle dosage treatment group, C group-low dose therapy group; Compare P＜0.05. with Y, Z group
3.4.1 liver function Z group ALT level is apparently higher than A group, B group, C group, but difference does not have significance; A group AST level is lower than Y group and Z group, and difference has significance (P＜0.05).
3.4.2 blood fat A group TC level is starkly lower than Y group and Z group, difference has significance P＜0.05); Z group TG level is higher than A group, B group, C group, but difference does not have significance; A group LDLC level is starkly lower than Y group and Z group, compares with the Z group, and difference has significance (P＜0.05).
3.4.3MDA be lower than the Z group with SOD A group, B group, C group MDA level, difference does not have significance; A group SOD level is apparently higher than Y group and Z group, and difference has significance (P＜0.05).
3.4.4 blood glucose A group blood sugar level is starkly lower than the Y group, difference has significance (P＜0.05).
3.5 the 16W end is respectively organized rat liver homogenate and respectively detected index A group liver homogenate TC level and be starkly lower than Y group and Z group, difference has significance (P＜0.05); Each organizes the TG level difference does not have significance; A group, B group, C group LDLC level are lower than the Z group, and difference does not have significance; A group, C group liver homogenate MDA level are lower than Z group and Y group, compare with the Z group, and difference has significance.
Embodiment 1
Prescription: 10 parts of Radix Salviae Miltiorrhizaes, 20 parts of Rhizoma Polygoni Cuspidati, 8 parts of Ganodermas, 34 parts of Herba Sedis.
Method for making: get 3.8 parts of Herba Sedis, be ground into fine powder, remaining Herba Sedi decocts with water secondary, 10,8 times of amount of water, 2 hours for the first time, 1.5 hours for the second time, collecting decoction filters, and filtrate is condensed into the thick paste that relative density is 1.10～1.20 (70～80 ℃ of mensuration); Get Ganoderma, add 4 times of amount ethanol, flooded 24 hours, inclining, it is standby to get supernatant, medicinal residues respectively flooded 12 hours with 75%, 50% ethanol successively, respectively incline and get supernatant, last press residue is collected press juice, merge with three supernatant, filter, filtrate recycling ethanol also is condensed into the thick paste that relative density is 1.10～1.20 (50 ℃ of mensuration), and is standby; Percolation under Radix Salviae Miltiorrhizae and Rhizoma Polygoni Cuspidati photograph fluid extract and the extractum item (" appendix IO of Chinese pharmacopoeia), make slowly percolation of solvent with 90% ethanol, the soluble component of waiting is filtered out fully, and diacolation liquid recycling ethanol also is condensed into the thick paste that relative density is 1.10～1.20 (70～80 ℃ of mensuration); The medicinal residues of Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati and Ganoderma add 10 times of water gagings and decoct secondary, each 1 hour, collecting decoction, filter, filtrate is condensed into the thick paste that relative density is 1.10～1.20 (70～80 ℃ of mensuration), gets above-mentioned four kinds of thick pastes, add the Herba Sedi fine powder, mixing is dried to dry extract, pulverizing in 80 ℃, the system granule, be pressed into 1000, coating, promptly.
Embodiment 2
Prescription: 15 parts of Radix Salviae Miltiorrhizaes, 5 parts of Rhizoma Polygoni Cuspidati, 4 parts of Ganodermas, 51 parts of Herba Sedis.
Method for making: get 15 parts of Herba Sedis, be ground into fine powder, remaining Herba Sedi decocts with water secondary, 10,8 times of amount of water, 2 hours for the first time, 1.5 hours for the second time, collecting decoction filters, and filtrate is condensed into the thick paste that relative density is 1.10～1.20 (70～80 ℃ of mensuration); Get Ganoderma, add 4 times of amount ethanol, flooded 24 hours, inclining, it is standby to get supernatant, medicinal residues respectively flooded 12 hours with 75%, 50% ethanol successively, respectively incline and get supernatant, last press residue is collected press juice, merge with three supernatant, filter, filtrate recycling ethanol also is condensed into the thick paste that relative density is 1.10～1.20 (50 ℃ of mensuration), and is standby; Percolation under Radix Salviae Miltiorrhizae and Rhizoma Polygoni Cuspidati photograph fluid extract and the extractum item (" appendix IO of Chinese pharmacopoeia), make slowly percolation of solvent with 90% ethanol, the soluble component of waiting is filtered out fully, and diacolation liquid recycling ethanol also is condensed into the thick paste that relative density is 1.10～1.20 (70～80 ℃ of mensuration); The medicinal residues of Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati and Ganoderma add 10 times of water gagings and decoct secondary, each 1 hour, collecting decoction, filter, filtrate is condensed into the thick paste that relative density is 1.10～1.20 (70～80 ℃ of mensuration), gets above-mentioned four kinds of thick pastes, adds the Herba Sedi fine powder, mixing, be dried to dry extract, pulverizing, system granule in 80 ℃, encapsulated 1000, promptly.
Claims (4)
1. a Chinese medicine composition that is used for non-alcoholic stellato-hepatitis is characterized in that comprising following bulk drugs: Radix Salviae Miltiorrhizae 5-15 part, Rhizoma Polygoni Cuspidati 10-30 part, Ganoderma 4-12 part, Herba Sedi 17-51 part.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that: 10 parts of Radix Salviae Miltiorrhizaes, 20 parts of Rhizoma Polygoni Cuspidati, 8 parts of Ganodermas, 34 parts of Herba Sedis.
3. Chinese medicine composition preparation method according to claim 1 and 2 is: Herba Sedi partly is ground into fine powder, and remaining Herba Sedi decocts with water secondary, collecting decoction, the thick paste that filters, is condensed into; Other gets Ganoderma, adds alcohol dipping three times, respectively inclines and gets supernatant, and last press residue is collected press juice, merges with three supernatant, filters, and reclaims ethanol and is condensed into thick paste, and is standby; Radix Salviae Miltiorrhizae and Rhizoma Polygoni Cuspidati are made slowly percolation of solvent with ethanol, and the soluble component of waiting is filtered out fully, and percolate reclaims ethanol and is condensed into thick paste; The medicinal residues of Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati and Ganoderma decoct with water secondary, filter the thick paste that filtrate is condensed into, get above-mentioned four kinds of thick pastes, add remaining Herba Sedi fine powder mixing, drying, pulverize, add suitable adjuvant, make capsule, tablet, drop, granule according to conventional operation.
4. according to the application of the described Chinese medicine composition of claim 1-3 in the medicine of preparation treatment treatment non-alcoholic stellato-hepatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010150807 CN101804102A (en) | 2010-04-20 | 2010-04-20 | Traditional Chinese medicine compound for nonalcoholic steatohepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010150807 CN101804102A (en) | 2010-04-20 | 2010-04-20 | Traditional Chinese medicine compound for nonalcoholic steatohepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101804102A true CN101804102A (en) | 2010-08-18 |
Family
ID=42606162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010150807 Pending CN101804102A (en) | 2010-04-20 | 2010-04-20 | Traditional Chinese medicine compound for nonalcoholic steatohepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101804102A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560779A (en) * | 2014-10-15 | 2016-05-11 | 上海中医药大学附属龙华医院 | Non-alcoholic fatty liver disease prevention and control compound preparation and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679891A (en) * | 2005-01-14 | 2005-10-12 | 郭来旺 | Method for producing capsules of Huganning for liver |
| CN101385783A (en) * | 2008-09-17 | 2009-03-18 | 李浪辉 | Huganning tablets for treating chronic and urgent liver disease and preparation method thereof |
-
2010
- 2010-04-20 CN CN 201010150807 patent/CN101804102A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679891A (en) * | 2005-01-14 | 2005-10-12 | 郭来旺 | Method for producing capsules of Huganning for liver |
| CN101385783A (en) * | 2008-09-17 | 2009-03-18 | 李浪辉 | Huganning tablets for treating chronic and urgent liver disease and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| <<中华人民共和国卫生部药品标准-中药成方制剂第十三册>> 19971231 卫生部药典委员会 护肝宁片 81 1-3 , 1 * |
| > 20051231 王鲁文等 护肝宁治疗非酒精性脂肪肝疗效观察 373-375 1-4 第13卷, 第6期 2 * |
| > 20081031 徐敏 护肝宁片联合二甲双胍治疗非酒精性脂肪肝病疗效观察 329-330 4 第16卷, 第5期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560779A (en) * | 2014-10-15 | 2016-05-11 | 上海中医药大学附属龙华医院 | Non-alcoholic fatty liver disease prevention and control compound preparation and use thereof |
| CN105560779B (en) * | 2014-10-15 | 2019-11-12 | 上海中医药大学附属龙华医院 | The compound preparation and application thereof for preventing and treating non-alcohol fatty liver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102631390B (en) | Preparation method of periploca forrestii schltr extract as well as product and application of periploca forrestii schltr extract | |
| CN101091765A (en) | Medicinal comsns-and usage for preventing and treating diabets mellitus | |
| CN103976124B (en) | A kind of preparation technology of root of kudzu vine candy | |
| CN102349975A (en) | Health care product formula of dendrobium officinale, composition as well as preparation method and application of composition | |
| CN103494928B (en) | Preparation method for compound houttuynia cordata preparation | |
| CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
| CN101559148A (en) | Pharmaceutical composition for treating diabetes and/or hyperlipemia and preparation method thereof | |
| CN102512438A (en) | Application of pseudostellaria polysaccharide in food for preventing and treating diabetes mellitus as well as health-caring | |
| CN102688283B (en) | Chinese traditional medicine capsule for treating lupus erythematosus and preparation method thereof | |
| CN104083510A (en) | Liver-protecting granule for poultry and preparation method thereof | |
| CN101693090B (en) | Technology for preparing compound kidney inflammation tablets | |
| CN102247413B (en) | Hypolipidemic effects of radix dipsaci total saponin and akebia stem saponin D | |
| CN101804102A (en) | Traditional Chinese medicine compound for nonalcoholic steatohepatitis | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN102552702B (en) | Application of Dendrobium officinale in preparing medicaments for treating low gastric acidity type chronic atrophic gastritis | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN102526237B (en) | Medicinal composition for removing advanced oxidation protein final product and application thereof | |
| CN103505628B (en) | A kind of application of Chinese medicine composition in preparing treatment ketoacidosis and merging leukemoid reaction medicine | |
| CN106562415A (en) | Health food and preparation method thereof | |
| CN104825880A (en) | Traditional Chinese medicine preparation for treating hyperlipemia and preparation method of traditional Chinese medicine preparation | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
| CN101716264B (en) | Medical composition for treating atherosclerosis, preparation method and application thereof | |
| CN101204504A (en) | Medicament composite for diabetes mellitus and preparation method threreof | |
| CN108497494A (en) | A kind of health food and preparation method thereof of auxiliary reducing blood lipid | |
| CN108210651A (en) | It is a kind of to be used to treat natural drug composition of diabetic nephropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100818 |